Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Sales | 41,337 | 38,432 | 42,177 | 40,340 | 38,800 |
| Cost of Goods | 1,178 | 1,613 | 1,174 | 925 | 797 |
| Gross Profit | 40,159 | 36,819 | 41,003 | 39,415 | 38,003 |
| Operating Expenses | 61,897 | 55,344 | 56,354 | 50,948 | 52,398 |
| Operating Income | -21,560 | -17,912 | -15,177 | -10,608 | -13,598 |
| Interest Expense | 1,057 | 1,155 | 2,972 | 660 | 658 |
| Other Income | 455 | 918 | 7,111 | -7,749 | -898 |
| Pre-tax Income | -22,162 | -18,149 | -11,038 | -19,017 | -15,154 |
| Income Tax | 167 | 229 | 6,580 | -1,223 | -1,925 |
| Net Income Continuous | -22,329 | -18,378 | -17,618 | -17,794 | -13,229 |
| Net Income | $-22,329 | $-18,378 | $-17,618 | $-17,794 | $-13,229 |
| EPS Basic Total Ops | -0.56 | -0.46 | -0.45 | -0.46 | -0.34 |
| EPS Basic Continuous Ops | -0.56 | -0.46 | -0.45 | -0.46 | -0.34 |
| EPS Diluted Total Ops | -0.56 | -0.46 | -0.42 | -0.46 | -0.34 |
| EPS Diluted Continuous Ops | -0.56 | -0.46 | -0.46 | -0.46 | -0.34 |
| EBITDA(a) | $-16,301 | $-13,208 | $-10,147 | $-5,163 | $-8,846 |